The Pharma Bloodbath Part III - 2026 Will Create 180,000 New Jobs and Destroy 95,000 Others – Here’s How to Be on the Right Side of That Equation

Andreas Schulz, #HIRING

#MoreThanCareer Executive Career Coach | Talent Acquisition & HR Partner Pharmaceuticals @Bayer | Job Search Strategy Consultant | 16 years Recruitment | CV & LinkedIn Profile Rewriting & Employer Branding

16th February 2026

Dear #MoreThanCareer community,

Part I ruined your Sunday brunch. Part II ruined your Monday. Part III is here to ruin your complacency – and then, begrudgingly, to fix it. Think of this as the trilogy nobody commissioned but the data insisted on. Like Der Untergang (Downfall), except instead of a bunker it’s an open-plan office, and instead of a dictator it’s a restructuring consultant from McKinsey with a slide deck and a complete absence of empathy. The ending is happier, though. Marginally.

This instalment is different. Parts I and II diagnosed the disease. Part III hands you the lab results, the prognosis, and a prescription that doesn’t cost €2,997 with a countdown timer. Because after 42,700 jobs lost in 2025 [1] and a 47% year-over-year increase in layoffs [2], the question is no longer “is the industry restructuring?” – that’s like asking if water is wet during a flood.

The question is: how many people will be hired, how many will lose their jobs, and what on earth separates the two groups?

I’ve done the maths. I’ve read the reports. I’ve consumed enough analyst forecasts to qualify for a therapy session. Let me show you what I found. Achtung, fertig, Schmerz. (Ready, set, pain.)

THE MATHS: WHAT THE DATA ACTUALLY PROJECTS FOR 2026

Let’s start with the number everyone wants and nobody can give you with certainty. I’ve synthesised projections from BioSpace, EY, Deloitte, PharmiWeb, EPM Scientific, and McKinsey – essentially everything short of reading tea leaves, though given the FDA’s recent track record with AI hallucinations, tea leaves might actually be more reliable. Here’s the honest answer:

 Global biopharma: estimated 140,000–180,000 new hires versus 75,000–95,000 projected job losses.

 That’s a net positive of roughly 55,000–85,000 jobs worldwide – the first net surplus since 2022. Before you pop the Sekt (sparkling wine) and compose a gratitude post: the 64% of biopharma organisations actively recruiting at end of 2025 [3] are not hiring the same profiles they’re firing. The 41% expecting to increase open roles in 2026 [4] want clinical data scientists, not the administrative coordinators who just received a separation package with a gift voucher for LinkedIn Premium. Andere Mutter, anderes Kind (Different mothers, different children) – the jobs being created and the jobs being destroyed are barely related.

EY projects total layoffs below 5% of industry headcount [5] – a meaningful deceleration from 2025’s carnival of terminations, but still representing tens of thousands of real people with real mortgages and a suddenly very real interest in the Arbeitsagentur (employment agency) website. Think of it as a blood transfusion: the body is receiving fresh blood while simultaneously haemorrhaging from a different vein. The net volume is improving, but try explaining that to the vein. Dem Arzt ist es egal, welche Ader blutet – dem Patienten nicht (The doctor doesn’t care which vein is bleeding – the patient does).

THE DACH EQUATION: WHERE THE JOBS ARE ARRIVING AND DEPARTING

For those of us whose careers depend on what happens between Flensburg and Innsbruck, with a detour through Basel:

DACH estimated net: +8,000 to +14,000 jobs (hiring of roughly 22,000–30,000 offset by 14,000–16,000 reductions).

Cautiously positive. Like a doctor telling you the tumour is benign but you should still come back in six months. And the waiting room is full of consultants from Deloitte.

Germany: Bayer’s restructuring has eliminated over 12,000 positions since mid-2023 [6], with the no-compulsory-redundancy agreement running until 31 December 2026 [7]. What happens after that date is a question that keeps more than a few Leverkusen-based professionals awake at night, staring at the ceiling and wondering whether Betriebsbedingte Kündigung (operational dismissal) is one word or two. Meanwhile: BioNTech continues expanding in Mainz and Marburg. Boehringer Ingelheim is investing in biologics manufacturing. The EU Life Sciences Strategy 2030, backed by a genuinely staggering €10 billion annually [8], specifically targets clinical research infrastructure and advanced manufacturing – areas where Germany has competitive advantage and Switzerland has competitive salaries. Man kann nicht alles haben (You can’t have everything).

Switzerland: Novartis’s 550 Stein cuts by 2027 versus 80 new siRNA roles at Schweizerhalle [9] is the kind of arithmetic that would get you arrested in banking but qualifies as “strategic portfolio alignment” in pharma. The $23 billion Novartis is investing in US manufacturing [10] tells you where the centre of gravity is heading: westward, across the Atlantic, presumably by business class. Pfizer’s Swiss operation went from 300 to roughly 70 [11]. That’s not downsizing. That’s a company Christmas party that now fits into a Raclette restaurant. For Swiss-based professionals: the opportunities are in specialised manufacturing, RNA therapeutics, and cross-border regulatory roles. Generalist positions are migrating. Nächster Halt: North Carolina. Bitte aussteigen. (Next stop: North Carolina. Please disembark.)

Austria: Comparatively stable, as Austria tends to be when Germany is having a crisis and Switzerland is having an identity rethink. Boehringer Ingelheim’s Vienna hub, Takeda, and the now-independent Sandoz continue as significant employers. The biosimilars space actually benefits from the patent cliff. Every blockbuster’s patent expiry is a biosimilar company’s Christmas, Easter, and Nationalfeiertag rolled into one. Des einen Leid, des anderen Freud (One person’s suffering is another’s joy) – the unofficial motto of the entire generics industry, printed on business cards nowhere but understood everywhere.

WHERE THE 180,000 NEW JOBS WILL ACTUALLY BE

Based on BioSpace, PharmiWeb, EPM Scientific, and Deloitte data [12][13][14], here are the sectors and functions driving hiring in 2026. Ranked by demand, because Germans don’t trust analysis that doesn’t come with a ranking, a table, or ideally both:

1. Clinical Operations and Development – The single largest hiring category. Decentralised and hybrid trial models are creating demand for CRAs, clinical project managers, and data managers faster than universities can produce them. Oncology remains the most competitive therapeutic area, which is ironic given that competition in oncology is supposed to benefit patients, not create an arms race for talent. In DACH, CROs are actively recruiting. If you have GCP certification and a pulse, someone wants to talk to you. Preferably both.

2. Data Science, AI and Computational Biology – 29% of surveyed companies plan to hire in technology roles in 2026 [15]. The “translator” profiles – people bridging domain science and data fluency – are the single hardest roles to fill [16]. McKinsey estimates 75–85% of pharma workflows could be enhanced by agentic AI [17]. That doesn’t mean 75% of people are replaced. It means 100% of people need to stop treating Excel as the pinnacle of digital innovation. Wer nicht mit der Zeit geht, geht mit der Zeit (Those who don’t move with the times will be moved by the times).

3. Manufacturing, Quality and Bioprocess Engineering – The reshoring boom is astonishing: US companies alone committed over $480 billion [18]. Eli Lilly’s $50 billion, Novartis’s $23 billion, Pfizer’s $70 billion. In DACH, biologics manufacturing, GMP quality, and CDMO operations are growing. Biomanufacturing engineers with automation expertise are in acute shortage. If you know your way around a bioreactor and a PLC controller, you’re not job hunting. You’re being hunted.

4. Regulatory Affairs and Pharmacovigilance – The EU’s new life sciences strategy, the evolving FDA chaos, and the tsunami of biosimilar submissions are creating sustained demand [19]. Regulatory professionals who understand AI-enabled submissions are especially valuable. Pharmacovigilance specialists with analytics capability are a growth category. If the words “signal detection algorithm” excite you rather than terrify you, congratulations: you’re employable.

5. Biosimilars and Generics – The $230 billion patent cliff [20] creates an entire parallel economy. Every Keytruda or Eliquis losing exclusivity spawns regulatory, manufacturing, commercial, and medical affairs roles. Sandoz, Fresenius Kabi, Teva, Viatris, and Celltrion are all expanding. The patent cliff is Big Pharma’s funeral and the biosimilar industry’s job fair. Same church, different pews.

6. Medical Communications and Market Access – HEOR, medical writing, and real-world evidence are growing as payers demand more data before opening their wallets. Medical communications agencies continue hiring scientists who can actually write – a combination as rare as a German who jaywalks. Schuster, bleib bei deinen Leisten (Cobbler, stick to your last) – unless your last is a pipette and the market wants a pen, in which case: switch.

A BRIEF GLOBAL DETOUR (FOR CONTEXT AND SCHADENFREUDE)

United States: Life sciences employment reached approximately 2.1 million – a record [21]. Simultaneously, the market bottomed out in Q4 2025 and recruiters expect only a “very gradual” recovery [22]. Contract hiring has surged: some recruiters report 30–40% more contract placements than permanent roles [23]. America: where you can be laid off on Monday, rehired as a contractor for your own job on Wednesday, and post about “resilience” on LinkedIn by Friday. The land of opportunity, redefined. Nur in Amerika brennt das Haus und der Makler verkauft es als “warm und hell” (Only in America does the house burn while the estate agent lists it as “warm and bright”).

Asia-Pacific: The counternarrative that makes DACH professionals quietly uncomfortable. APAC CRO market: $13.7 billion in 2024, projected to nearly double by 2033 [24]. Jiangsu Hengrui overtook AstraZeneca as the world’s top clinical trial sponsor [25]. For DACH professionals with international ambitions: Asia didn’t just emerge. It arrived, unpacked, redecorated, and is now asking why you haven’t visited. Wer zu spät kommt, den bestraft das Leben (Those who arrive too late are punished by life) – Gorbachev said it about the Berlin Wall. It applies equally to career planning.

Europe: The EU Life Sciences Strategy 2030 is the most significant policy signal in a decade. The sector supports 29 million jobs and contributes €1.5 trillion to the EU economy [26]. The “Choose Europe for Science” initiative now offers US researchers fast-track visas, lab space, and multi-year grants [27] – essentially poaching American scientists with the same enthusiasm America usually reserves for poaching European ones. The irony is köstlich (delicious). Whether EU bureaucracy will let this ambition translate into actual hired humans remains the perennial European question. Gut gemeint ist der böse Bruder von gut gemacht (Well intended is the evil brother of well done).

THE TOP 5 CAREER ACTIONS THAT WILL ACTUALLY MATTER IN 2026

No motivational platitudes. No manifesting. No “unlock your inner pharma warrior” webinars for three easy payments of €999. These are five evidence-based actions drawn from recruiter data, hiring patterns, and the accumulated scar tissue of sixteen years watching what works versus what merely generates LinkedIn impressions. Versprechen und Halten sind zweierlei (Promising and delivering are two different things). I’m delivering.

1. NICHE DOWN YOUR CV – SPECIFICITY IS THE NEW CURRENCY

Three senior recruiters at BioSpace’s latest hiring webinar delivered one unanimous verdict: niche yourself down rather than appealing to the broadest audience [28]. Competition has intensified to 4.2 applications per posting, up from 3.6 a year ago [29]. In that environment, a generic CV is a generic rejection letter waiting to happen.

Practically: “Managed clinical trials” tells a recruiter precisely nothing. “Led four Phase III oncology trials across 18 sites in DACH and CEE, achieving 96% enrollment targets within timeline using risk-based monitoring” tells them everything. Be the scalpel, not the Swiss Army knife. The Swiss Army knife is impressive at dinner parties. The scalpel gets hired.

Juniors: You can’t niche into experience you don’t have. But you can niche into a direction. Choose a therapeutic area. Learn its language. Reference actual compounds and mechanisms in your cover letter. A trainee applicant who mentions the company’s pipeline by name is already ahead of 200 competitors who are “passionate about pharmaceutical innovation” – a phrase so generic it could apply equally to a scientist and a PowerPoint template.

50+ professionals: Your niche is depth and Gelassenheit (composure). Focus on the last 10–15 years. Lead with institutional knowledge no algorithm can replicate. You’ve survived patent cliffs, three restructurings, and that time the CEO announced a “cultural transformation” that turned out to be new office furniture. You’re not outdated. You’re the corporate equivalent of load-bearing walls – nobody notices you until someone tries to remove you and the ceiling collapses.

2. LEARN ONE DIGITAL SKILL THIS QUARTER – NOT TO CHANGE CAREERS, BUT TO KEEP YOURS

41% of life sciences executives identified generative AI as an influential trend for 2026 [30]. Yet only 9% reported seeing returns on AI investments [31]. My success rate at finding matching socks in the morning is higher. Companies are investing heavily in technology they haven’t figured out, and they desperately need people who can bridge science and digital. The “translator” profile commands a 15–20% market premium and is the hardest to hire. [16] 78% of C-suite executives expect AI to play a central role [32]. That’s not a trend. That’s a stampede.

Practically: Take one course in data analytics, Python, or AI fundamentals. Not to become a data scientist – to become a scientist who can discuss a dashboard without nodding along pretending to understand. Coursera, DataCamp, edX: under €200. That’s less than what most LinkedIn gurus charge for a motivational PDF with stock photos of lighthouses. Wer billig kauft, kauft zweimal (Buy cheap, buy twice) – but in this case, the cheap option is actually better. The expensive option is usually a man named Stefan with a ring light.

Executives: Your digital skill is strategic AI literacy. Understanding where AI creates genuine value versus expensive demos that impress nobody who actually works in the lab. Stop adding “AI-Powered” to your LinkedIn headline. Start understanding what the technology actually does. The difference is the difference between leadership and decoration.

3. THINK CONTRACTS, NOT JUST PERMANENT CONTRACTS – THE PARALLEL ECONOMY IS REAL

Senior recruiters report 30–40% more contract placements than permanent hiring – a seismic shift [33]. Companies have work that needs doing but no headcount approval to do it. The result: a booming parallel economy of contract, consulting, and project-based roles that entirely bypasses traditional hiring freezes. Wo eine Tür sich schließt, öffnet sich ein Werkvertrag (Where one door closes, a service contract opens) – not as poetic as the original, but significantly more accurate in 2026.

Practically: If you’re exclusively waiting for a permanent position at your dream company, you may be waiting through the best opportunities of the year. A six-month contract at IQVIA or Parexel is not a demotion. It’s a credential, a network expansion, income, and – critically – something to say at family dinners besides “the market is challenging” while your mother-in-law silently judges your life choices between bites of Schweinebraten (roast pork).

International candidates in DACH: Contract roles can be more complex with visa requirements, but not impossible. Many CROs and consulting firms have frameworks for temporary work permits. Ask explicitly. The worst answer is nein, and nein is survivable. Germans say it approximately forty times before breakfast anyway.

4. TARGET SECTORS, NOT LOGOS – THE ECOSYSTEM IS VASTLY BIGGER THAN THE HEADLINES

100% of companies with 500–999 employees were actively recruiting, versus just 37% of those with fewer than 50 [34]. But the real insight is beyond company size: the pharma ecosystem includes thousands of CROs, CDMOs, medical comms agencies, regulatory consultancies, health tech companies, and specialised service providers that hire without ever making a LinkedIn headline. Stille Wasser sind tief (Still waters run deep) – and they’re full of job openings you haven’t considered.

Growing sectors in DACH: Biosimilars (patent cliff beneficiaries). CROs (trial volumes rising globally). CDMOs and advanced manufacturing (biologics, RNA). Regulatory and pharmacovigilance consultancies. Medical communications. Health tech. And, in a twist of cosmic irony: outplacement agencies.

Senior leaders and executives: Advisory and board roles. Goldman Sachs projects roughly $3.9 trillion in M&A deal flow in 2026 [35], with pharma M&A already running ahead of 2024 pace [36]. Where there are deals, there are integration teams. Where there are integration teams, there are people who’ve done this before and know where the bodies are buried. Figuratively, of course. Erfahrung ist der beste Lehrer – aber das Lehrgeld ist hoch (Experience is the best teacher – but the tuition is expensive). You’ve already paid. Now cash in.

5. YOUR NETWORK IS A PENSION FUND. STOP TREATING IT LIKE A FIRE EXTINGUISHER.

I said this in Parts I and II. The response confirmed it’s the advice everyone agrees with and nobody follows. Networking is the dental floss of career management: universally recommended, universally neglected, and only desperately adopted when something is already painfully wrong.

28% of companies will recruit remote candidates regardless of location in 2026, up from 20% last year and 16% the year before [37]. When geography matters less, referrals matter more. When a hiring manager has 200 applicants, the differentiator is whether someone inside can vouch for you. That person doesn’t materialise through Vitamin B (connections, literally “Vitamin B” for Beziehungen) – they materialise because you invested in the relationship twelve months ago, when you didn’t need anything. Freundschaft, die der Wein macht, wirkt wie der Wein nur eine Nacht (Friendship made over wine lasts only as long as the wine) – build relationships that survive sobriety.

International candidates: German employers value Zuverlässigkeit (reliability) above nearly everything. A referral from inside the company signals stability, cultural fit, and language investment. Build those relationships now. Not when the Kündigungsfrist (notice period) is already ticking.

50+ professionals: Your network is your nuclear option. The executives making hiring decisions are your former colleagues, your conference acquaintances, your fellow survivors of that team-building event in Bad Homburg in 2014 that involved a ropes course and a HR manager who cried. Those connections are irreplaceable. No 28-year-old with a TikTok about “career hacks” can replicate what you’ve built over two decades. Use it. Alte Liebe rostet nicht (Old love doesn’t rust) – and neither do professional relationships forged in genuine shared experience.

THE BLOOD TRANSFUSION: A CLOSING DIAGNOSIS

2026 is not 2025. January layoffs dropped to 463 from over 1,300 [38]. Seventy-five percent of life sciences executives rate their outlook positive; in Europe, 90% [39]. The XBI biotech index recovered over 30% from its April 2025 lows [40]. Cell and gene therapy investment reached $15.2 billion, up 30% from 2023 [41]. The building is being renovated, not demolished. Though the noise level is roughly the same, and someone has definitely stolen the good coffee machine from the break room.

The industry is not dying. It is metamorphosing – absorbing new capabilities, excreting obsolete structures, and growing in directions that would have been unrecognisable five years ago. The question is whether you are metamorphosing with it, or standing in the corridor holding a clipboard wondering when things will go back to normal. Spoiler: nie. (Spoiler: never.)

Wer rastet, der rostet. (He who rests, rusts.) My grandmother said that. Usually while handing me a second Schnapps and a third piece of unsolicited career advice. She was right about both.

If you’re secure: prepare anyway. The universe has no contractual obligation to respect your comfort zone. If you’re worried: act on the five steps above – today, not after the third Riesling. If you’ve been affected: reach out. Write me in the comments or DM me. I don’t have a €2,997 course to sell you. I have sixteen years of experience, an honest assessment, and a stubborn belief that competent, prepared professionals find their way through – even when the way involves a temporary detour via the Arbeitsagentur and explaining to your Schwiegermutter (mother-in-law) why you’re suddenly available for Tuesday lunch. Das Leben ist kein Ponyhof (Life is not a pony farm). But it’s not a slaughterhouse either. Somewhere between those two equine metaphors lies the truth about 2026.

The bloodbath is becoming a blood transfusion. New blood is entering. The question is whether your veins are connected to the right supply. The five actions above? That’s your IV drip. Use it.

Prost! 🍺

NEVER MISS AN EDITION

If this article was useful, subscribe to my LinkedIn newsletter #MoreThanCareer to get Part IV (yes, it’s coming) and all future editions delivered directly to your inbox and LinkedIn notifications:

 How to subscribe: Click the “Subscribe” button at the top of this newsletter page. That’s it. No countdown timer. No three easy payments. No upsell. Just career intelligence for pharmaceutical professionals, delivered whenever I have something worth saying – which, according to my colleagues, is more often than strictly necessary.

YOUR TURN:

1. Which of the five career actions are you actually going to implement this month? (Answers involving “manifesting”, “aligning my chakras”, or “trusting the process” will be filed directly into my “things that don’t generate income” folder.)

2. Has the contract/project economy affected your career strategy in DACH? Are you seeing more temporary roles? Share your experience – your data point might be someone else’s lifeline.

3. For those who’ve jumped from Big Pharma to a CRO, CDMO, or consultancy: what surprised you most? What do you wish someone had told you? Besides “the coffee is worse.”

4. International professionals in DACH: what’s the single most underrated challenge when building a pharma career in Germany, Switzerland, or Austria? I’m collecting these for Part IV. Yes, there will be a Part IV. Vorsprung durch Planung. (Progress through planning.) Audi’s marketing team should really return my calls.

5. 50+ professionals: what’s one piece of advice you’d give your 35-year-old self about career resilience? The industry needs your perspective more than it needs another think piece about disruption.

6. Did the five actions miss something critical? Tell me what I got wrong. I’m German. We can take criticism. We just process it internally for six to eight weeks before outwardly acknowledging it. Then we improve. Quietly. And thoroughly.

 Like what you read? Please give me a follow by clicking this link:

https://www.linkedin.com/in/schulzandreas1/

Please don’t forget to click the bell to activate notifications for all my posts & articles!

💾 Save this post to build your own free library of career advice! Click the little flag/banner to the left of the three dots up to the right.

 #TeamBayer #MoreThanCareer #PharmaJobs #Recruiting #CareerAdvice 

SOURCES

[1] BioSpace Hiring Outlook, Feb 2026. ~42,700 employees affected by layoffs in 2025. https://www.biospace.com/job-trends/hiring-outlook-january-brings-year-over-year-layoff-decline

[2] PharmaVoice, Jan 2026. Biopharma layoffs rose 16% YoY; 47% increase in affected employees. https://www.pharmavoice.com/news/layoffs-biopharma-2026-drug-pharma/810386/

[3] BioSpace 2026 Employment Outlook. 64% actively recruiting (up from 59%). https://www.biospace.com/job-trends/hiring-plans-show-promise-for-biopharma-job-seekers-biospace-report

[4] BioSpace 2026 Employment Outlook. 41% predict open roles will increase. https://www.biospace.com/job-trends/hiring-plans-show-promise-for-biopharma-job-seekers-biospace-report

[5] PharmaVoice, Jan 2026. EY: total layoff percentage likely below 5% in 2026. https://www.pharmavoice.com/news/layoffs-biopharma-2026-drug-pharma/810386/

[6] Xtalks, Pharma & Biotech Layoffs 2025. Bayer: 12,000+ eliminated since 2023. https://xtalks.com/pharma-and-biotech-layoffs-2025-4110/

[7] Bayer AG, Jan 2024. No compulsory redundancies until end of 2026. https://www.bayer.com/media/en-us/bayer-aims-to-sustainably-improve-performance-with-new-organization/

[8] European Commission, Jul 2025. EU Life Sciences Strategy 2030. https://research-and-innovation.ec.europa.eu/strategy/strategy-research-and-innovation/jobs-and-economy/strategy-european-life-sciences_en

[9] Fierce Pharma, Nov 2025. Novartis: 550 cuts Stein, 80 new Schweizerhalle. https://www.fiercepharma.com/manufacturing/novartis-lays-out-plan-cut-550-jobs-plant-switzerland-end-2027

[10] Novartis, Apr 2025. $23B US investment over five years. https://www.novartis.com/us-en/news/media-releases/novartis-plans-expand-its-us-based-manufacturing-and-rd-footprint-total-investment-23b-over-next-5-years

[11] BioSpace Layoff Tracker 2025. Pfizer Switzerland: 300 to ~70. https://www.biospace.com/biospace-layoff-tracker

[12] PharmiWeb, Jan 2026. Life Science Hiring Trends 2026. https://www.pharmiweb.jobs/article/life-science-hiring-trends-and-challenges-heading-into-2026

[13] EPM Scientific, 2026. Life Sciences Careers 2026 hiring trends. https://www.epmscientific.com/en-us/industry-insights/career-advice/life-sciences-careers-2026-top-hiring-trends

[14] Deloitte 2026 Life Sciences Outlook. https://www.deloitte.com/us/en/insights/industry/health-care/life-sciences-and-health-care-industry-outlooks/2026-life-sciences-executive-outlook.html

[15] BioSpace 2026 Employment Outlook. 29% expect to hire in technology roles. https://www.biospace.com/job-trends/hiring-plans-show-promise-for-biopharma-job-seekers-biospace-report

[16] PharmiWeb, 2026. Translator profiles hardest to hire; 15-20% premium. https://www.pharmiweb.jobs/article/life-science-hiring-trends-and-challenges-heading-into-2026

[17] NES Fircroft / McKinsey, 2026. 75-85% pharma workflows enhanced by AI. https://www.nesfircroft.com/resources/blog/whats-next-for-the-life-sciences-sector-top-trends-in-2026/

[18] GEN, Jan 2026. $480B+ in US reshoring commitments. https://www.genengnews.com/insights/trends-for-2026/seven-biopharma-trends-to-watch-in-2026/

[19] EPM Scientific, 2026. Regulatory and PV demand drivers. https://www.epmscientific.com/en-us/industry-insights/career-advice/life-sciences-careers-2026-top-hiring-trends

[20] GEN, Nov 2025. $230B in blockbuster sales facing LOE by 2030. https://www.genengnews.com/topics/drug-discovery/top-20-drugs-heading-for-the-patent-cliff-2026-2029/

[21] Artech, Jan 2026. US life sciences: ~2.1 million workers. https://www.artech.com/blog/pharmaceutical-careers-2026-key-roles-market-trends/

[22] BioSpace, Feb 2026. Market bottomed Q4 2025; gradual recovery. https://www.biospace.com/job-trends/7-key-insights-into-the-2026-job-market-and-hiring-landscape

[23] BioSpace, Feb 2026. 30-40% more contract than permanent hiring. https://www.biospace.com/job-trends/7-key-insights-into-the-2026-job-market-and-hiring-landscape

[24] EPM Scientific / Grand View Research. APAC CRO market $13.7B. https://www.epmscientific.com/en-us/industry-insights/career-advice/life-sciences-careers-2026-top-hiring-trends

[25] PharmaVoice, Jan 2026. Chinese biotech licensing; Hengrui overtook AZ. https://www.pharmavoice.com/news/layoffs-biopharma-2026-drug-pharma/810386/

[26] European Commission, Jul 2025. Life sciences: EUR 1.5T value, 29M jobs. https://commission.europa.eu/news-and-media/news/making-europe-global-leader-life-sciences-2025-07-02_en

[27] Serendi / European Commission. Choose Europe for Science EUR 500M initiative. https://www.serendi.com/post/pharma-recruitment

[28] BioSpace, Feb 2026. Recruiter advice: niche down. https://www.biospace.com/job-trends/7-key-insights-into-the-2026-job-market-and-hiring-landscape

[29] BioSpace, Feb 2026. 4.2 apps/posting Jan 2026 vs 3.6 Jan 2025. https://www.biospace.com/job-trends/hiring-outlook-january-brings-year-over-year-layoff-decline

[30] Deloitte 2026. 41% cited gen AI as influential trend. https://www.deloitte.com/us/en/insights/industry/health-care/life-sciences-and-health-care-industry-outlooks/2026-life-sciences-executive-outlook.html

[31] PharmaVoice, Jan 2026. Only 9% reported ROI on AI investments. https://www.pharmavoice.com/news/layoffs-biopharma-2026-drug-pharma/810386/

[32] GEN, Jan 2026. 78% C-suite expect AI central role. https://www.genengnews.com/insights/trends-for-2026/seven-biopharma-trends-to-watch-in-2026/

[33] BioSpace, Feb 2026. Contract hiring surge: 30-40% shift. https://www.biospace.com/job-trends/7-key-insights-into-the-2026-job-market-and-hiring-landscape

[34] BioSpace 2026. 100% of 500-999 employee companies actively recruiting. https://www.biospace.com/job-trends/hiring-plans-show-promise-for-biopharma-job-seekers-biospace-report

[35] Foley & Lardner, Sep 2025. Goldman Sachs: ~$3.9T M&A deal flow. https://www.foley.com/insights/publications/2025/09/patent-cliff-ma-activity-for-companies-right-now/

[36] Deloitte 2026. Pharma M&A $91.9B Q1-Q3 2025 vs $61.7B full 2024. https://www.deloitte.com/us/en/insights/industry/health-care/life-sciences-and-health-care-industry-outlooks/2026-life-sciences-executive-outlook.html

[37] BioSpace, Feb 2026. Remote hiring: 28% up from 20% and 16%. https://www.biospace.com/job-trends/employers-warm-up-to-remote-workers-again-biospace-report

[38] BioSpace, Feb 2026. Jan 2026: 463 affected vs 1,302 in Jan 2025. https://www.biospace.com/job-trends/hiring-outlook-january-brings-year-over-year-layoff-decline

[39] Deloitte 2026. 75% positive outlook; 90% in Europe. https://www.deloitte.com/us/en/insights/industry/health-care/life-sciences-and-health-care-industry-outlooks/2026-life-sciences-executive-outlook.html

[40] IntuitionLabs / BioSpace. XBI recovered 30%+ from April 2025 lows. https://intuitionlabs.ai/articles/life-sciences-job-market-2025

[41] NES Fircroft, 2026. CGT investment $15.2B in 2025, +30% vs 2023. https://www.nesfircroft.com/resources/blog/whats-next-for-the-life-sciences-sector-top-trends-in-2026/

© 2026 Andreas Schulz. All rights reserved.